Johnson & Johnson (NYSE:JNJ - Get Free Report) had its target price hoisted by equities research analysts at Morgan Stanley from $169.00 to $171.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Morgan Stanley's price objective would indicate a potential upside of 8.30% from the company's current price.
JNJ has been the subject of a number of other reports. Bank of America reduced their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $171.00.
Check Out Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Stock Up 1.0%
JNJ traded up $1.62 during trading on Thursday, reaching $157.90. The stock had a trading volume of 2,910,571 shares, compared to its average volume of 9,001,193. The stock's 50 day moving average is $153.67 and its two-hundred day moving average is $154.27. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $379.91 billion, a price-to-earnings ratio of 17.57, a P/E/G ratio of 2.36 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.
Institutional Trading of Johnson & Johnson
Several institutional investors and hedge funds have recently modified their holdings of the stock. MRP Capital Investments LLC raised its holdings in shares of Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after purchasing an additional 65 shares during the last quarter. Syverson Strege & Co increased its position in Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after buying an additional 65 shares in the last quarter. Elios Financial Group Inc. lifted its holdings in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC increased its stake in Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after buying an additional 67 shares in the last quarter. Finally, MBA Advisors LLC lifted its holdings in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares in the last quarter. Institutional investors own 69.55% of the company's stock.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
